BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicine. We ...

Lunai Bioworks shares pivotal updates on its biodefense initiative, precision neurology projects, and measures to protect shareholder value amid market challenges.

Lunai Bioworks, Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular p...

The collaboration aims to link patient subtypes identified by BioSymetrics, Lunai's subsidiary, with cellular mechanisms.

Lunai Bioworks (LNAI) reported a BioSymetrics case study showing AI-based screening of chemical structures for acetylcholinesterase (AChE) inhibition, aimed at supporting chemical-risk controls for generative AI outputs.Using NIH Tox21 AChE assay data on 9,667 compounds, the selected model achieved an AUROC of 0.88 and 33% precision at 70% recall, corresponding to about 5.1-fold enrichment over the dataset’s 6.4% prevalence of AChE‑active entries. The structure-based screen is designed to operate independently of any specific large language model or molecular-generation system and to act as a downstream layer that prioritizes molecules for further computational, expert, or biological review.The work extends a multi-year, revenue-generating defense collaboration that links mechanism-of-action modeling with in vivo zebrafish phenotypic screening, and underpins more than US$30 million in submitted, but not yet awarded, non-dilutive grant applications in chemical defense and biosecurity.

BioSymetrics is a phenomics-driven drug discovery company that integrates clinical and experimental data, using machine learning, to translate human disease biology and advance precision medicine. We ...